Summary Primitive neuroectodermal tumours (PNET's) or medulloblastomas are common primary brain tumours of childhood. Current treatment protocols achieve 50-60% cures. However, it has proved difficult to develop better treatment for the remaining patients because prognostic factors are not established. We have investigated the prognostic value of p53 protein expression in 87 PNET's using immunohistochemistry with DO-7 and CM-1 antibodies on biopsy paraffin sections. Eight patients (9%) had intensely reactive tumour cell nuclei, and a significantly reduced survival (P = 0.002); only one survives and this with a recurrent tumour 50 months following diagnosis. Sixty eight per cent of patients had faintly reactive tumour cell nuclei, a reduced survival up to 4 years but a long term survival not significantly different (P = 0.41) from 23% of patients with p53 negative PNET's; the 10 year survival rates were 37% and 40%, respectively. Males had a reduced survival (P = 0.04) with a 2-fold relative risk of death compared to females. Multivariate analysis showed that intense overexpression of p53 protein identifies a group of PNET patients with a 7-fold relative risk of death compared to all other cases, irrespective of sex. This marked difference suggests the involvement of p53 in the pathogenesis of PNET's which have a particularly poor response to treatment, and should help to develop new therapies for this group of patients.
Primitive neuroectodermal tumours (PNET's) represent between 20 to 25% of all primary brain tumours of childhood. They develop most frequently in the cerebellum when they are usually known as medulloblastomas. Although fatal if untreated, current treatment regimens achieve 50-60% 5-year survival rates for medulloblastomas (Tait et al., 1990) . At the present time neither clinical nor histopathological features in medulloblastomas reliably identify which tumours will recur (Caputy et al., 1987) , making it difficult to develop new therapeutic strategies. A recent Newcastle study has shown that mitotic index and overexpression of the c-erbB2 protooncogene have some prognostic value in medulloblastomas (Gilbertson et al., 1992) , and this led to an examination of additional molecular biological features of PNET's and their use as prognostic markers.
Derangements in-the tumour suppressor gene p53, which maps to chromosome l7pl3.1 (Solomon & Barker, 1989) may be involved in the pathogenesis of PNET's since 11 of 34 informative cases show loss of constitutional heterozygosity for polymorphic markers on chromosome 17pl 1.2-pter (James et al., 1990; Raffel et al., 1990) . Mutations in the p53 gene led to accumulation of p53 protein to 10-100-fold above normal values (Reich et al., 1983; Iggo et al., 1990) . At these concentrations immunohistochemically detectable p53 have been shown to be associated with malignant progression and poor prognosis in a variety of human tumours, including astrocytoma . Although previous studies have identified overexpression of p53 in some PNET's Barbareschi et al., 1992; Loda et al., 1992) , the number of cases examined was too small to assess its prognostic value. In this report we have used p53 antibodies effective on paraffin sections (Rorke et al., 1985) . Eighty of the PNET's (92%) came from the cerebellum and could therefore be classified as medulloblastoma (Russell & Rubinstein, 1989 ; Table I ). Seven (8%) of the tumours came from extracerebellar sites. None of these extracerebellar tumours fulfilled the diagnostic criteria for cerebral neuroblastoma (Russell & Rubinstein, 1989) , they all had areas where tumour cells had nuclear and cytoplasmic characteristics indistinguishable from medulloblastomas (for further details see footnotea in Table I ). The majority of patients had been treated with surgical resection plus cerebrospinal irradiation, a smaller group had surgery combined with radio-and chemotherapy, and only a small proportion of patients had been treated with surgery alone (Table II) .
Immunohistochemistry
The sections were incubated with mouse monoclonal antibodies to human p53 protein (DO-7; Novocastra) at a 1:50 dilution, or with rabbit polyclonal antibodies to human p53 protein (CM-1 from Novocastra) at a 1:500 dilution. The antibody binding was visualised using the ABC kit (Vectastain) followed by diaminobenzidine at 0.5 mg mlh-' and a haematoxylin counterstain, as described previously . Sections from a glioblastoma multiforme, overexpressing p53 protein, were used as positive controls for both the DO-7 and the CM-1 antibodies. Negative control sections were achieved by omitting the primary antibodies.
Whole sections from each PNET were examined at x 400 magnification and, where appropriate, the proportion of tumour cell nuclei with detectable levels of p53 was calculated using a squared graticule. The total number of nuclei counted in each PNET ranged between 700 to 1000 cells. The p53 labelling index (LI) was calculated as a percentage of p53 reactive, vs total number of tumour cell nuclei (LI = (group A) was from the left occipital lobe and had histopathological features indistinguishable from cerebellar medulloblastoma; it was negative for synaptophysin (Syn, marker for neuronal differentiation) but had focal positivity for glial fibrillary acidic protein (GFAP, marker for astrocytic differentiation); this patient was alive at last assessment though with recurrent tumour and spinal metastases. The second PNET (group A) was from the right fronto-parietal lobe and had areas indistinguishable from medulloblastoma plus areas with multinucleated giant cells; it had focal positivity for both Syn and GFAP (died). The third PNET (group B) was a cauda equina metastasis occurring 9 years after a diagnosis of cerebellar medulloblastoma with which it shared its histopathological features and focal Syn and GFAP positivity (alive). The fourth PNET (group B) was from the left fronto-temporal lobe and had features indistinguishable from cerebellar medulloblastoma with focal GFAP positivity but was negative for Syn (died). The fifth PNET (group C) was from the third ventricle and right hypothalamus and had features indistinguishable from cerebellar medulloblastoma with focal positivity for GFAP but was negative for Syn (alive with recurrent tumour). The sixth PNET (group D) was from the base of the spine (L4/5) and had nuclear and cytoplasmic features of a PNET with focal Syn positivity; there was no evidence on histopathological or immunohistochemical grounds of it being an ependymoma, chordoma, astrocytoma, teratoma or nerve sheath tumour (alive). The seventh PNET (group C) was from the right fronto-parietal lobe; it had areas indistinguishable from cerebellar medulloblastoma plus areas with oligodendroglial-like histology; it had focal GFAP positivity but was negative for Syn (alive). bp = 0.75, d.f. = 3; CP = 0.0007, 95% Confidence Interval for differences in medians (12.4, 42.0); dp = 0.13, d.f. = 51; ep= 0.04, d.f. = 51; P = 0.006, d.f. = 51; gP= 0.065, d.f. = 51; hp = 0.14, 
Statistical analysis
Since the data for p53 LI and age were not normally distributed a Mann-Whitney test was used to analyse differences in p53 LI (Siegel & Castelan, 1988) . The median ages of the reactive groups A, B, C and D were compared using the Kruskal-Wallis test (Siegel & Castelan, 1988 (Peto et al., 1977) . Sex and the continuous variables, i.e. age and p53 LI were also separately entered into the Cox regression model (Cox, 1972) Figure 1) Table I ). There was no significant difference between the mean MI's of groups B, C, and D. All groups were similarly heterogeneous with respect to sex, age, and site of tumour (Table I) , and treatment they received (Table II) . The differences in median ages between the four groups were not significant (KruskalWallis test P = 0.75).
Prognostic significance ofp53 reaction intensity, p53 labelling index, sex, and age Univariate Log-Rank test for categorised variables was used to analyse the prognostic importance of p53 reaction intensity and sex. PNET patients from groups B and C had similar life tables (P = 0.63) allowing them to be pooled into one 'faintly-reactive' group (59 cases), which represented 68% of all the patients. The eight patients in group A with intensely reactive tumour cell nuclei had a significantly reduced survival (P = 0.002) compared to the 'faintlyreactive' (pooled group B and C) and negative cases (group D); only one of these patients (13%) has survived 50 months following diagnosis, and this patient is currently suffering from a recurrent tumour (Figure 3 ). The patients with faintly reactive nuclei (pooled B and C) had a reduced survival during the first 4 years compared to the patients with negative (D) PNET's (P = 0.037) but the long term survival was similar in the two groups (P = 0.42); the 10 year survival rates were 37% and 40% respectively, using the Kaplan-Meier estimates. Of the seven tumour specimens derived from extracerebellar sites five were alive at the last clinical assessment, one of them from group A ( Table I ). The extracerebellar PNET's therefore did not contribute to the increased mortality observed in group A.
Males had a significantly reduced survival than females (P = 0.04); the 10 year survival rates were 29% and 47%, respectively, using Kaplan-Meier estimates (Figure 4) (Table IV) . Only sex was significant (P = 0.04), while age and p53 LI were not (P = 0.11, P = 0.33, respectively). Note also, that being male increases the relative risk of death compared to being female by 1.9 times. Therefore, the effect of age and p53 LI was adjusted for sex, when using multivariate analysis by forward stepwise application of Cox's regression model (Table V) . Although the significance of both variables increased to borderline statistical significance when adjusted for sex P = 0.052, P = 0.072, respectively), the actual adjusted effect was very small, as can be seen from virtually identical relative risks for age and p53 LI in Tables IV and V. Multivariate analysis of the prognostic importance of all the variables examined in this and the previous study (Gilbertson et al., 1992) , together with the histopathological and immunohistochemical features of the PNET's and the various treatment regimens the patients received will be a subject of a separate paper.
Discussion
This study has demonstrated that p53 immunohistochemistry with DO-7 antibodies detects p53 protein overexpression in tumour cell nuclei of PNET's at two levels, intense and faint, but that only the intense overexpression identifies a group of 9% of patients with a particularly poor prognosis. High p53 labelling index, without regard for the p53 reaction intensity, was not of prognostic importance. These observations suggest that intense p53 overexpression is associated with greater tumour growth potential and/or tumour promoting activity than the faint p53 overexpression. The precise molecular mechanisms underlying these differences is not known at present, although experiments designed to elucidate the relationship are in progress. The wild type (wt) p53 protein is involved in negative regulation of cell growth (Finlay et al., 1988) . In normal quiescent cells it has a short half-life of about 6-30 min, and is present at low cellular levels, undetectable by immunohistochemistry (Reich et efficiencies (Hinds et al., 1990) , and p53 mutations alone do not appear to be able to transform cells. To effect full transformation p53 mutants require the cooperation of activated ras and/or myc oncogenes (Reihsaus et al., 1990) . Furthermore, though the cell lines immortalised by p53 mutations also show accumulation of p53 with moderately increased half-lives (to about 1 h), only their transformation with activated ras and/or myc oncogenes leads to vastly elevated levels of mutant p53 with half-lives further extended to 10 h (Gjerset et al., 1992) . This suggests that in most PNET patients with intense or high level of p53 overexpression and poor prognosis (group A), the DO-7 antibody has detected mutant forms with mutations in exons 5 to 8, and that the cooperation of activated oncogenes or other tumour suppressor genes is likely to be involved, both in the level of overexpression and in the transformation efficiency of p53.
Candidate genes for cooperation with p53 in PNET's have yet to be identified. Amplification, rearrangement, or mutation of c-myc (Raffel et al., 1990; Bigner et al., 1990; MacGregor & Ziff, 1990) , overexpression of the c-erbB2 protooncogene (Gilbertson et al., 1992) and/or non-random abnormalities of chromosomes 1, 6, or 16 reported to occur in subgroups of PNET's (Griffin et al., 1988; Thomas & Raffel, 1991) suggest possible candidates and others will no doubt follow as the genetic alterations in PNET's are further characterised. Several observations indicate that non-mutational mechanisms can also lead to high levels of p53 overexpression in cells, though because of their relative rarity they are unlikely to be an explanation for the p53 overexpression in the bulk of the PNET's. First, wt p53 may be overexpressed due to an aberrant expression of cellular transcriptional regulators of the p53 gene (Ronen et al., 1991) . High level of p53 mRNA expression has so far been detected in one medulloblastoma cell line (Loda et al., 1992) and hence requires further investigation. Second, complex formation between wt p53 and viral oncogenes (Reich et al., 1983 ) is unlikely to be responsible for the intense p53 overexpression, since there is no evidence of a viral aetiology for PNET's. A further alternative is aberrant post-translational processing of wt p53, as recently reported as a germ-line defect in a family with cancer predisposition (Barnes et al., 1992 ). The faint or low level of p53 overexpression identified in 68% of PNET patients with an intermediate prognosis (pooled groups B and C) may have several explanations. The DO-7 antibody reacts with both the wt and the mutant forms of human p53 protein . It has a greatly improved sensitivity compared to the Pab 1801 antibody which we employed originally . The wt p53 can become elevated to about 3-4-fold above levels found in quiescent cells, either in mitogenstimulated cells through regulation of p53 at the level of transcription (Reich & Levine, 1984) , or in response to treatment with DNA damaging agents through post-translational stabilisation mechanism (Kastan et al., 1991) . It is possible that in some PNET's from group B and C the DO-7 antibody has detected the wt p53 which became elevated through the first of these two mechanisms. The faint reactivity with the DO-7 antibody in the hyperplastic endothelial nuclei of 7% of the PNET's supports this possibility. However, the DNA damaging agents are unlikely to be involved in any of the PNET's since all the samples were obtained prior to radio-or chemo-therapy. Alternatively, in groups B and C the DO-7 antibody may have detected moderately elevated levels of p53 mutants, similar to those that occur in non-transformed but immortalised cell lines in the absence of contributory effects from activated oncogenes (Gjerset et al., 1992) . Lastly, the similar long-term survival rates of PNET patients in the faintly reactive group and the negative group suggests that in the negative group either abnormalities in genes other than p53 are involved in their development or that the p53 gene is affected by large deletions, splicing and nonsense mutations, or missense mutations outside of exons 5 to 8, as all these abnormalities can lead to loss of p53 function in the absence of p53 expression (Bodner et al., 1992) .
This investigation has identified a group of PNET patients whose particularly poor response to treatment is associated with intense or high level of p53 overexpression. The high level of p53 accumulation is likely to be associated with mutations in the p53 gene, and to effect full transformation, the p53 mutants may cooperate with other oncogenes and/or tumour suppressor genes. Survival of PNET patients appears to be dependent on sensitivity of their tumours to radiation therapy (Ito et al., 1992) . The poor response of PNET's expressing high levels of p53 suggests that they are less sensitive to radiotherapy than tumours showing low levels of p53 immunoreactivity. This runs counter to the previous proposals that p53 abnormalities may make tumour cells more responsive to DNA damaging agents (Lane, 1992; Vogelstein & Kinzler, 1992) . However, more recently it has been demonstrated that wild type p53 is essential for the apoptic response of thymocytes to ionising radiation (Lowe et al., 1993; Clarke et al., 1993) , and it has been proposed that abrogation of the p53 pathway may be involved in the poor response of many human tumours to treatment by radiation and chemotherapeutic drugs (Lane, 1993) . It remains to be established whether such p53 mediated responses are relevant to PNET's. We are currently engaged in DNA sequencing studies to further elucidate the relationship between the intensity of p53 overexpression, p53 gene mutation, and survival in PNET patients.
